TY -的T1 -治疗Anti-CD20 Therapy-Resistant Neuromyelitis视与白细胞介素- 6受体封锁:一个案例系列(S60.003) JF -神经学乔-神经病学SP - S60.003 LP - S60.003六世- 80 - 7补充AU - Ingo K首页leiter盟Ilya Ayzenberg AU -亚历山德拉·施罗德盟Kerstin Hellwig AU - Andrew Chan盟拉尔夫黄金Y1 - 2013/02/12 UR - //www.ez-admanager.com/content/80/7_Supplement/S60.003.abstract N2 -目的:报告第一次经验与白介素(IL) 6受体抑制治疗耐药Neuromyelitis视(动)。背景:b细胞消耗治疗似乎是最有前途的在动,但大约有20%的病人仍然经历复发。il - 6应该发挥关键作用在动,直接激活特定plasmablast族群秘密aquaporin-4抗体。il - 6的receptor-blocking抗体叫动可能是一个新的治疗选择。设计/方法:我们回顾性研究的功效叫2006年根据修订Wingerchuk动病人诊断标准,谁没有回应记者的b细胞消耗与利妥昔单抗治疗。复发年率(ARR)、残疾进展测量扩展残疾状况得分(eds)和脊髓MRI活动进行了分析。结果:我们报告3女性患者的平均年龄39岁(26-40)年aquaporin-4-positive动。所有患者治疗不同的免疫抑制和immunomodulating代理,其次是1 - 3周期的利妥昔单抗。尽管完成CD20-cell损耗在利妥昔单抗治疗,加勒比海盗中值为3.0(2.3 - -3.0)和eds中值增加从5.0 (4.5 - -7.0),6.5 (5.0 - -7.0)。后切换到叫(中位治疗18个月时间),加勒比海盗中值下降到0.6 (0 - 1.3)。总共2复发发生,然而,他们是温和的,没有临床残疾或MRI疾病活动的变化。除了2轻微感染没有不良事件。CONCLUSIONS: The IL-6 receptor-blocking therapy can be effective in therapy resistant cases of NMO. Larger controlled studies are needed to confirm the efficacy of tocilizumab.Disclosure: Dr. Kleiter has received personal compensation for activities with Bayer, Biogen Idec, Merck Serono, and Novartis. Dr. Kleiter has received research support from Bayer, Novartis, Biogen Idec, and Merck Serono. Dr. Ayzenberg has nothing to disclose. Dr. Schröder has nothing to disclose. Dr. Hellwig has received personal compensation for activities with Bayer, Biogen Idec, Merck Serono, Teva, and Novartis. Dr. Hellwig has received research support from Bayer, Biogen Idec, Merck Serono, Novartis and Teva/Sanofi Aventis. Dr. Chan has received personal compensation for activities with Bayer Schering, Biogen Idec, Merck Serono, Sanofi-Aventis and Teva Neuroscience as a speaker or consultant. Dr. Chan has received research support from the German Ministry for Education and Research (BMBF, German Competence Network Multiple Sclerosis (KKNMS), CONTROL MS, 01GI0914), Bayer Schering, Biogen Idec, Merck Serono and Novartis. Dr. Gold has received personal compensation for activities with Bayer HealthCare, Biogen Idec, Merck Serono, Novartis, and Teva Neuroscience. Dr. Gold has received personal compensation in an editorial capacity for Therapeutic Advances in Neurological Disorders. Dr. Gold has received a license fee from Biogen Idec. Dr. Gold has received research support from Bayer HealthCare, Biogen Idec, Merck Serono, Novartis, and Teva Neuroscience.Thursday, March 21 2013, 2:00 pm-3:30 pm ER -